Nelly Kuklin, PhD

Nelly Kuklin, PhD, joined Compass Therapeutics in 2020, bringing 20 years of drug discovery experience in the biotech and pharmaceutical industries. Prior to Compass, Nelly was a Senior Director of Translational Research at Gemini Therapeutics where she successfully developed and executed a clinical biomarker strategy for Age-related Macular Degeneration. Before that, from 2011-2015, Dr. Kuklin led drug development programs in the area of rare diseases and headed the biomarker department at Alexion Pharmaceuticals. In that role, Nelly developed and directed biomarkers strategies for a large program portfolio from discovery to pivotal trials. Earlier in her career, Nelly advanced through various scientific positions of increasing responsibility at Merck & Co. where ahe successfully led oncology and vaccine programs, including Staphylococcus, Human Papilloma Virus vaccine (Gardasil), and an IgF1R monoclonal antibody from discovery to pivotal trials. As a department head, she built and managed teams of more than 17 scientists and technical personnel.

Nelly holds a PhD in immunology from the University of Tennessee and performed post-doctoral training in immunology at Stanford University. She is an author of over 36 peer reviewed publications and patents.